Abstract

Poxvirus systems have been extensively used as vaccine vectors. Herein a RNA-Seq analysis of intramuscular injection sites provided detailed insights into host innate immune responses, as well as expression of vector and recombinant immunogen genes, after vaccination with a new multiplication defective, vaccinia-based vector, Sementis Copenhagen Vector. Chikungunya and Zika virus immunogen mRNA and protein expression was associated with necrosing skeletal muscle cells surrounded by mixed cellular infiltrates. The multiple adjuvant signatures at 12 hours post-vaccination were dominated by TLR3, 4 and 9, STING, MAVS, PKR and the inflammasome. Th1 cytokine signatures were dominated by IFNγ, TNF and IL1β, and chemokine signatures by CCL5 and CXCL12. Multiple signatures associated with dendritic cell stimulation were evident. By day seven, vaccine transcripts were absent, and cell death, neutrophil, macrophage and inflammation annotations had abated. No compelling arthritis signatures were identified. Such injection site vaccinology approaches should inform refinements in poxvirus-based vector design.

Highlights

  • Only one recombinant poxvirus vectored vaccine has to date been licensed for human use, with ongoing efforts seeking to enhance immunogenicity whilst minimizing reactogenicity

  • A range of vaccine vector systems based on vaccinia virus (VACV) and other poxviruses have been developed, with several sold as products and many more in development and in human clinical trials [1]

  • A large series of recombinant Modified Vaccinia Ankara (MVA) vaccines have been evaluated in non-human primate (NHP) studies [10] and in human clinical trials [1,11], with MVA-BN-Filo recently licensed in Europe as part of a heterologous prime-boost Ebola vaccine [12]

Read more

Summary

Introduction

A range of vaccine vector systems based on vaccinia virus (VACV) and other poxviruses have been developed, with several sold as products and many more in development and in human clinical trials [1] These include Modified Vaccinia Ankara (MVA) [2,3], NYVAC [4], ALVAC [5], fowlpox [6], LC16m8 [7], ACAM2000 [8] and raccoonpox [9]. A range of strategies are being sought to improve immunogenicity and reduce reactogenicity [2,13,14,15,16,17] Both these key characteristics of vaccines are largely dictated by the early behavior of the vaccine at the injection site. A comprehensive RNA-Seq approach to characterize the post-inoculation injection site responses has not been undertaken for a recombinant poxvirus-based vaccine

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call